NASDAQ:AXSM Axsome Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $38.53 +1.50 (+4.05%) (As of 06/28/2022 11:39 AM ET) Add Compare Share Today's Range$34.84▼$39.7050-Day Range$21.74▼$43.0452-Week Range$19.38▼$74.10Volume70,167 shsAverage Volume680,558 shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice Target$82.72 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Stock Forecast (MarketRank)Overall MarketRank™2.27 out of 5 starsMedical Sector295th out of 1,436 stocksPharmaceutical Preparations Industry124th out of 687 stocksAnalyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $82.72, Axsome Therapeutics has a forecasted upside of 125.4% from its current price of $36.70.Amount of Analyst CoverageAxsome Therapeutics has received no research coverage in the past 90 days. Previous Next 4.8 Community Rank Outperform VotesAxsome Therapeutics has received 377 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAxsome Therapeutics has received 152 “underperform” votes. (Add your “underperform” vote.)Community SentimentAxsome Therapeutics has received 71.27% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote “Outperform” if you believe AXSM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.00% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.46% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($3.95) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 89.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axsome Therapeutics (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock News HeadlinesJune 27, 2022 | nasdaq.comCheap Stocks To Buy Today? 3 Health Care Stocks For Your WatchlistJune 27, 2022 | marketwatch.comAxsome Therapeutics Shares Leap on Renewed AXS-05 Hopes >AXSMJune 27, 2022 | markets.businessinsider.comAxsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains SkepticalJune 27, 2022 | finance.yahoo.comAxsome Therapeutics Stock Soars on Proposed FDA Labeling for Depression DrugJune 27, 2022 | investorplace.comAxsome Therapeutics (AXSM) Stock Soars on FDA Labeling ProposalJune 27, 2022 | seekingalpha.comHot Stocks: CHWY and ML rise on upgrades, AXSM surges, and ETSY falls on downgradeJune 27, 2022 | seekingalpha.comAxsome surges 50% as FDA issues proposed labeling for depression drugJune 27, 2022 | markets.businessinsider.comWhy Axsome Therapeutics Stock Is Soaring TodayJune 27, 2022 | finance.yahoo.comTesla's Up as Stock-Split Investors Wait, But This Tiny Nasdaq Stock Is Riding High MondayJune 22, 2022 | finance.yahoo.comAxsome Therapeutics to Host Sunosi® Investor Update Virtual EventJune 13, 2022 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $83.22 Average Price Target from AnalystsJune 6, 2022 | finance.yahoo.comAxsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual MeetingJune 3, 2022 | benzinga.comAXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud LawsuitSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees108Year FoundedN/ACompany Calendar Last Earnings5/02/2022Today6/28/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$82.72 High Stock Price Forecast$180.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+114.7%Consensus RatingModerate Buy Rating Score (0-4)2.88888888888889 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-389.71% Return on Assets-129.08% Debt Debt-to-Equity Ratio3.36 Current Ratio3.54 Quick Ratio3.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book93.98Miscellaneous Outstanding Shares38,910,000Free Float28,796,000Market Cap$1.50 billion OptionableOptionable Beta2.49 Axsome Therapeutics Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Axsome Therapeutics stock. View analyst ratings for Axsome Therapeutics or view top-rated stocks. What is Axsome Therapeutics' stock price forecast for 2022? 9 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM stock forecasts range from $34.00 to $180.00. On average, they predict Axsome Therapeutics' share price to reach $82.72 in the next year. This suggests a possible upside of 112.0% from the stock's current price. View analysts' price targets for Axsome Therapeutics or view top-rated stocks among Wall Street analysts. How has Axsome Therapeutics' stock performed in 2022? Axsome Therapeutics' stock was trading at $37.78 at the beginning of 2022. Since then, AXSM stock has increased by 3.3% and is now trading at $39.02. View the best growth stocks for 2022 here. When is Axsome Therapeutics' next earnings date? Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Axsome Therapeutics. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Monday, May, 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by $0.01. During the same quarter last year, the business earned ($0.78) EPS. View Axsome Therapeutics' earnings history. Who are Axsome Therapeutics' key executives? Axsome Therapeutics' management team includes the following people: Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 54, Pay $1.06M)Mr. Nick Pizzie CPA, M.B.A., Chief Financial Officer (Age 47, Pay $553.97k) (LinkedIn Profile)Mr. Mark L. Jacobson, COO & Sec. (Age 39, Pay $554.72k)Mr. Hunter Murdock Esq., Exec. VP of Legal & ComplianceDr. Amanda Jones Pharm.D., Sr. VP of Clinical Devel. (Age 39)Ms. Lori Englebert M.B.A., Exec. VP of Commercial & Bus. Devel. (Age 44)Mr. Kevin Laliberte Pharm.D., Exec. VP of Product Strategy (Age 44)Joseph Debrah-Afful CPA, M.B.A., Director of Fin. Who are some of Axsome Therapeutics' key competitors? Some companies that are related to Axsome Therapeutics include Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Intra-Cellular Therapies (ITCI), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Evotec (EVTCY), Cerevel Therapeutics (CERE), Ultragenyx Pharmaceutical (RARE), Cytokinetics (CYTK), Mirati Therapeutics (MRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG) and Karuna Therapeutics (KRTX). View all of AXSM's competitors. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.94%), BlackRock Inc. (5.38%), Alethea Capital Management LLC (2.68%), Fairmount Funds Management LLC (2.42%), Bellevue Group AG (1.85%) and State Street Corp (1.80%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs. View institutional ownership trends for Axsome Therapeutics. Which major investors are selling Axsome Therapeutics stock? AXSM stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Alethea Capital Management LLC, State Street Corp, BNP Paribas Arbitrage SA, Goldman Sachs Group Inc., Jane Street Group LLC, BlackRock Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for Axsome Therapeutics or view top insider-selling stocks. Which major investors are buying Axsome Therapeutics stock? AXSM stock was purchased by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, Ghost Tree Capital LLC, Worth Venture Partners LLC, Graham Capital Management L.P., Bellevue Group AG, Peregrine Capital Management LLC, Endurant Capital Management LP, and Simplex Trading LLC. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, Nick Pizzie, and Roger Jeffs. View insider buying and selling activity for Axsome Therapeutics or or view top insider-buying stocks. How do I buy shares of Axsome Therapeutics? Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $39.02. How much money does Axsome Therapeutics make? Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $1.52 billion. The company earns $-130.40 million in net income (profit) each year or ($3.72) on an earnings per share basis. How many employees does Axsome Therapeutics have? Axsome Therapeutics employs 108 workers across the globe. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for Axsome Therapeutics is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245. This page (NASDAQ:AXSM) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
